Business
Lifshitz & Miller Law Firm Announces Investigation of 3D Systems Corporation, Avalanche Biotechnologies, Inc., FXCM Inc., KYTHERA Biopharmaceuticals, Inc., root9B Technologies Inc., and Ryland Group Inc.
Lifshitz & Miller Law Firm Announces Investigation of 3D Systems Corporation, Avalanche Biotechnologies, Inc., FXCM Inc., KYTHERA Biopharmaceuticals, Inc., root9B Technologies Inc., and Ryland Group Inc..
About this update from Root9b Holdings Inc
[{"type":"text","content":"\n\n\n\nLifshitz & Miller Law Firm Announces Investigation of 3D Systems Corporation, Avalanche Biotechnologies, Inc., FXCM Inc., KYTHERA Biopharmaceuticals, Inc., root9B Technologies Inc., and Ryland Group Inc.\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nLifshitz & Miller Law Firm Announces Investigation of 3D Systems Corporation, Avalanche Biotechnologies, Inc., FXCM Inc., KYTHERA Biopharmaceuticals, Inc., root9B Technologies Inc., and Ryland Group Inc.\nPR Newswire\nNEW YORK, June 19, 2015\n\n\n\nNEW YORK, June 19, 2015 /PRNewswire/ --\n\n3D Systems Corporation \n\nLifshitz & Miller  announces investigation into possible breaches of fiduciary duties by the board of 3D Systems Corporation (DDD).  Specifically, we are investigating DDD's representations in connection with DDD's (i) ability to increase the capacity of its metal printing business; (ii) demand for its consumer products; (iii) the value of multiple companies it was acquiring; and (iv) expected earnings.\n\nFor more information about our investigation, please contact Joshua M. Lifshitz, Esq. by telephone at (516) 493-9780 or by sending an e-mail including your contact information to: [email protected].\n\nAvalanche Biotechnologies, Inc. \n\nLifshitz & Miller  announces investigation into possible breaches of fiduciary duties by the board of Avalanche Biotechnologies, Inc. (AAVL).  Specifically, on June 15, 2015, AAVL announced that AAVL's treatment for wet age-related macular degeneration met its primary endpoint, but raised concerns by saying the study wasn't designed to show statistically significant differences between the active and control subjects in the secondary endpoints.\n\nFor more information about our investigation, please contact Joshua M. Lifshitz, Esq. by telephone at (516) 493-9780 or by sending an e-mail including your contact information to: [email protected].\n\nFXCM Inc. \n\nLifshitz & Miller  announces investigation into possible breaches of fiduciary duties by the board of FXCM Inc. (FXCM).  Specifically, we are investigating FX...